Dopamine D2/D3 Agonists with potent iron chelation, antioxidant and neuroprotective properties: Potential implication in symptomatic and neuroprotective treatment of parkinson's disease

ChemMedChem

Volumn 6, Issue 6, 2011, Pages 991-995

  Gogoi, Sanjib ^a   Antonio, Tamara ^b   Rajagopalan, Subramanian ^c   Reith, Maarten ^b   Andersen, Julie ^c   Dutta, Aloke K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Dopamine agonists; Iron chelation; Multifunctional drugs; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; ASCORBIC ACID; D 264; D 369; D 385; D 390; D 412; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; VK 28; ANTIOXIDANT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; IRON CHELATING AGENT; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING ASSAY; CELL COUNT; CELL LOSS; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IRON CHELATION; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SUBSTANTIA NIGRA; ANIMAL; CELL LINE; CHEMISTRY; CHO CELL; CRICETULUS; DRUG POTENTIATION; HAMSTER;

ANIMALS; ANTIOXIDANTS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; IRON CHELATING AGENTS; MICE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 79957597364     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201100140     Document Type: Article

References (34)

1. G. F. Wooten in Movement Disorders: Neurologic Principles and Practice, (Eds.: R.L. Watts, W.C. Koller), McGraw-Hill Professional Publishing, New York, 1997, pp153-160.
2. W. Paulus, K. Jellinger, J. Neuropathol. Exp. Neurol. 1991, 50, 743-755.
3. T. B. Sherer, R. Betarbet, J. T. Greenamyre, Curr. Opin. Invest. Drugs 2001, 2, 657-662.
4. C. D. Marsden, J. D. Parkes, Lancet 1976, 307, 292-296.
5. M. G. Spillantini, M. L. Schmidt, V. M. Lee, J. Q. Trojanowski, R. Jakes, M. Goedert, Nature 1997, 388, 839-840.
6. C. W. Olanow, W. G. Tatton, Annu. Rev. Neurosci. 1999, 22, 123-144.
7. J. Xu, S. Y. Kao, F. J. Lee, W. Song, L. W. Jin, B. A. Yankner, Nat. Med. 2002, 8, 600-606.
8. E. V. Mosharov, K. E. Larsen, E. Kanter, K. A. Phillips, K. Wilson, Y. Schmitz, D. E. Krantz, K. Kobayashi, R. H. Edwards, D. Sulzer, Neuron 2009, 62, 218-229.
9. S. S. Park, E. M. Schulz, D. Lee, Eur. J. Neurosci. 2007, 26, 3104-3112.
10. D. Berg, M. Gerlach, M. B. Youdim, K. L. Double, L. Zecca, P. Riederer, G. Becker, J. Neurochem. 2001, 79, 225-236.
11. E. Sofic, P. Riederer, H. Heinsen, H. Beckmann, G. P. Reynolds, G. Hebenstreit, M. B. Youdim, J. Neural. Transm. 1988, 74, 199-205.
12. D. T. Dexter, F. R. Wells, A. J. Lees, F. Agid, Y. Agid, P. Jenner, C. D. Marsden, J. Neurochem. 1989, 52, 1830-1836.
13. J. M. Gorell, R. J. Ordidge, G. G. Brown, J. C. Deniau, N. M. Buderer, J. A. Helpern, Neurology 1995, 45, 1138-1143.
14. B. Wolozin, N. Golts, Neuroscientist 2002, 8, 22-32.
15. I. Paris, P. Martinez-Alvarado, S. Cardenas, C. Perez-Pastene, R. Graumann, P. Fuentes, C. Olea-Azar, P. Caviedes, J. Segura-Aguilar, Chem. Res. Toxicol. 2005, 18, 415-419.
16. B. A. Faucheux, M. E. Martin, C. Beaumont, S. Hunot, J. J. Hauw, Y. Agid, E. C. Hirsch, J. Neurochem. 2002, 83, 320-330.
17. A. Gaeta, R. C. Hider, Br. J. Pharmacol. 2005, 146, 1041-1059.
18. S. J. Chinta, J. K. Andersen, Biochim. Biophys. Acta 2008, 1780, 1362-1367.
19. N. Ostrerova-Golts, L. Petrucelli, J. Hardy, J. M. Lee, M. Farer, B. Wolozin, J. Neurosci. 2000, 20, 6048-6054.
20. D. Kaur, J. K. Andersen, Aging Cell 2002, 1, 17-21.
21. W. Zhu, W. Xie, T. Pan, P. Xu, M. Fridkin, H. Zheng, J. Jankovic, M. B. Youdim, W. Le, FASEB J. 2007, 21, 3835-3844.
22. M. Shamoto-Nagai, W. Maruyama, H. Yi, Y. Akao, F. Tribl, M. Gerlach, T. Osawa, P. Riederer, M. Naoi, J. Neural. Transm. 2006, 113, 633-644.
23. A. Goswami, P. Dikshit, A. Mishra, S. Mulherkar, N. Nukina, N. R. Jana, Biochem. Biophys. Res. Commun. 2006, 342, 184-190.
24. S. Gal, H. Zheng, M. Fridkin, M. B. Youdim, Neurotoxic. Res. 2010, 17, 15-27.
25. S. Brar, D. Henderson, J. Schenck, E. A. Zimmerman, Arch. Neurol. 2009, 66, 371-374.
26. A. Cavalli, M. L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, M. Recanatini, C. Melchiorre, J. Med. Chem. 2008, 51, 347-372.
27. B. Ghosh, T. Antonio, M. E. Reith, A. K. Dutta, J. Med. Chem. 2010, 53, 2114-2125.
28. S. Biswas, S. Hazeldine, B. Ghosh, I. Parrington, E. Kuzhikandathil, M. E. Reith, A. K. Dutta, J. Med. Chem. 2008, 51, 3005-3019.
29. M. d'HardemareAdu, N. Alnaga, G. Serratrice, J. L. Pierre, Bioorg. Med. Chem. Lett. 2008, 18, 6476-6478.
30. B. Girennavar, G. K. Jayaprakasha, Y. Jadegoud, G. A. Nagana Gowda, B. S. Patil, Bioorg. Med. Chem. 2007, 15, 3684-3691.
31. B. Halliwell, J. M. Gutteridge, O. I. Aruoma, Anal. Biochem. 1987, 165, 215-219.
32. U. Ungerstedt, Eur. J. Pharmacol. 1968, 5, 107-110.
33. D. Kaur, F, Yantiri, S. Rajagopalan, J. Kumar, J. Q. Mo, R. Boonplueang, V. Viswanath, R. Jacobs, L. Yang, F. M. Beal, D. DiMonte, I. Volitaskis, L. Ellerby, R. A. Cherny, A. I. Bush, J. K. Andersen, Neuron 2003, 37, 899-909.
34. C. Li, S. Biswas, X. Li, A. K. Dutta, W. Le, J. Neurosci. Res. 2010, 88, 2513-2523.